Compare DexCom, Inc. (DXCM) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs HSBC Holdings plc — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while HSBC Holdings plc trades at $93.32 (market cap $319.39B). The key difference: HSBC Holdings plc is far larger — about 10× DexCom, Inc.'s market cap, and HSBC Holdings plc pays a 4% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and HSBC Holdings plc for 36 Days on average.
| DXCM | HSBC | |
|---|---|---|
Market Cap | $31.81B | $319.39B |
Volume | 2,861,821 | 2,543,839 |
Sector | Health | Financials |
52-Week High | $92.34 | $107.86 |
52-Week Low | $54.84 | $65.67 |
Typical Hold Time | 62 Days | 36 Days |
Enterprise Value | $31.26B | $216.95B |
Dividend Yield | — | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
HSBC trades at $93.71, down 3.97% today, with bearish technical signals dominating. The stock shows solid fundamentals with a P/E of 13.39 and net income margin of 34.54%, while recent earnings show mixed results with two beats and one miss. Recent corporate developments include expansion in technology banking and wealth management services, alongside strategic exits from lower-growth markets like Germany.
The outlook remains cautiously optimistic given strong profitability metrics and strategic growth initiatives, though near-term technical weakness and CFO transition risks warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings, reflecting balanced views on HSBC's Asia-focused growth strategy versus execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
